Novartis Sues Dr. Reddy's Over ANDA For Cancer Drug

Law360, New York (February 6, 2014, 2:45 PM EST) -- Novartis AG sued Dr. Reddy's Laboratories Ltd. on Wednesday, saying the generics maker's plan to market and sell its own version of blockbuster cancer drug Gleevec would infringe a Novartis patent.

Novartis said in a Delaware federal court complaint that Dr. Reddy's abbreviated new drug application would violate the patent for Gleevec, U.S. Patent Number 6,894,051, issued in 2005.

"Patents are vital to the ability of innovative companies like Novartis to invest in high-risk research. ... We have confidence in the integrity of the Gleevec patent...
To view the full article, register now.